Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Classical hematology 2

Conditions

Anemia, Refractory, with Excess of Blasts 271Leukemia, Myeloid, Acute 258Myelodysplastic Syndromes 254Anemia 245Leukemia 228Neoplasms 211Precursor Cell Lymphoblastic Leukemia-Lymphoma 182Leukemia, Myelomonocytic, Chronic 151Multiple Myeloma 138Venous Thromboembolism 137Myeloproliferative Disorders 131Leukemia, Lymphocytic, Chronic, B-Cell 126Lymphoma 119Lymphoma, Non-Hodgkin 118Thrombocytopenia 117Hodgkin Disease 103Anemia, Aplastic 97Febrile Neutropenia 86Hematologic Neoplasms 82Anemia, Refractory 82Primary Myelofibrosis 81Lymphoma, Follicular 81Congenital Abnormalities 81Leukemia, Myeloid, Chronic-Phase 74Leukemia, Myelogenous, Chronic, BCR-ABL Positive 73Blast Crisis 72Leukemia, Myeloid, Accelerated Phase 69Lymphoma, Mantle-Cell 68Neoplasms, Plasma Cell 66Myelodysplastic-Myeloproliferative Diseases 65

Interventions

enasidenib 1canakinumab 1X-Rays 1Specimen Handling 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Clonal Cytopenia of Undetermined Significance × Classical hematology × Clear all
NCT05102370 2026-01-27

A Study of Enasidenib in People With Clonal Cytopenia of Undetermined Significance

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
4 enrolled
Classical hematology

Clonal Cytopenia of Undetermined Significance

NCT05641831 2026-01-02

Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study

Ohio State University Comprehensive Cancer Center

Phase 2 Recruiting
110 enrolled
Classical hematology

Clonal Cytopenia of Undetermined Significance

Data powered by HemOnc (CC BY 4.0) Colophon âš¡